Comparative safety of two recombinant hepatitis B vaccines in children: Data from the vaccine adverse event reporting system (VAERS) and vaccine safety datalink (VSD)

Journal of Clinical Epidemiology

Volumn 51, Issue 6, 1998, Pages 503-510

  Niu, Manette T ^a   Rhodes, Philip ^b   Salive, Marcel ^a   Lively, Thomas ^a   Davis, David M ^a   Black, Steven ^c   Shinefield, Henry ^c   Chen, Robert T ^b   Ellenberg, Susan S ^a  

^a Div of Biostatist and Epidemiology   (United States)

^b CENTERS FOR DIS CONTR AND PREV   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

Adverse events; Children; Hepatitis B vaccine; Vaccine safety; VAERS; VSD

Indexed keywords

RECOMBINANT HEPATITIS B VACCINE;

AGITATION; ARTICLE; CHILD; CHILDHOOD; COMPARATIVE STUDY; CONVULSION; DATA ANALYSIS; DRUG SAFETY; FEVER; HEPATITIS B; HOSPITALIZATION; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; INFANT; MAJOR CLINICAL STUDY; NEWBORN; NORMAL HUMAN; ORGANIZATION AND MANAGEMENT; PRIORITY JOURNAL; RASH; SAFETY; SIDE EFFECT; STUPOR; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CONSUMER PRODUCT SAFETY; HEPATITIS B VACCINES; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; RETROSPECTIVE STUDIES; RISK; UNITED STATES;

EID: 0031831245     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(98)00014-6     Document Type: Article

References (45)

1. Centers for Disease Control Hepatitis B virus. A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: Recommendations of the Immunization Practices Advisory Committee (ACIP) MMWR. 40(Suppl. RR-13):1991;11-13.
2. American Academy of Pediatrics 1994 Red Book. Report of the Committee on Infectious Diseases, 23rd Edition:1994;American Academy of Pediatrics, Elk Grove Village, IL.
3. American Academy of Family Physicians. Age Charts for Periodic Health Examination. Kansas City, MO: American Academy of Family Physicians; 1994. (Reprint no. 510).
4. Advisory Committee on Immunization Practices, American Academy of Pediatrics, American Academy of Family Physicians, and the National Immunization Program, Centers for Disease Control and Prevention Recommended childhood immunization schedule - United States, January 1995. MMWR. 44:1995;574-575.
5. Recombivax HB, Engerix-B. In: Physician Desk Reference (PDR). Montvale, NJ: Medical Economics Data Production Company; 1995: 1628-1630, 2371-2373.
6. Andre F.E. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med. 87(Suppl. 3A):1989;14S-20S.
7. FDA. Summary for Basis of Approval, Merck Sharp & Dohme - hepatitis B vaccine (recombinant) - Recombivax HB, No. 85-053 (data on file). Washington, DC: Federal Drug Administration; 1985.
8. FDA. Summary for Basis of Approval, SmithKline Biologicals - Engerix B, No. 87-0556 (data on file). Washington, DC: Federal Drug Administration; 1987.
9. FDA. Summary Basis of Approval, Merck Sharp & Dohme - hepatitis B vaccine (recombinant) - Recombivax HB, No. 88-0192 (data on file). Washington, DC: Federal Drug Administration; 1988.
10. West D.J. Clinical experience with hepatitis B vaccine. Am J Infect Control. 17:1989;172-180.
11. McLean A.A., Hilleman M.R., McAleer W.J., Buynak E.B. Summary of worldwide clinical experience with H-B-Vax (B, MSD). J Infect. 7(Suppl. 1):1983;95-104.
12. Greenberg D.P. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. Pediatr Infect Dis J. 12:1993;438-445.
13. Zajac B.A., West D.J., McAller W.J., Scolnick E.M. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect. 13(Suppl. A):1986;39-45.
14. McMahon B.J., Helminiak C., Wainwright R.B., Bulkow L., Trimble B.A. Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. Am J Med. 92:1992;254-256.
15. Andre F.E. Clinical experience with a recombinant DNA hepatitis B vaccine. Southeast Asian J Trop Med Pub Health. 19:1988;501-510.
16. Andre F.E., Safary A. Summary of clinical findings on Engerix-B, a genetically engineered yeast-derived hepatitis B vaccine. Postgrad Med J. 63(Suppl. 2):1987;169-177.
17. Andre F.E. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine. 8(Suppl.):1990;S74-S78.
18. Lee C.Y., Huang L.M., Chang M.H., Hsu C.Y., Wu S.J., Sung J.L.et al. The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen-positive-hepatitis B surface antigen carrier mothers. Pediatr Infect Dis J. 10:1991;299-303.
19. Moyes C.D. Hepatitis B vaccination. N Z Med J. 107:1994;238-239.
20. Yeoh E.K., Chang W.K., Ip P., Chan K.H., Chan E., Fung C. Efficacy and safety of recombinant hepatitis B vaccine in infants born to HBsAg-positive mothers. J Infect. 13(Suppl. A):1986;15-18.
21. Gunn T.R., Bosley A., Woodfield D.G. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates. N Z Med J. 102:1989;1-3.
22. Meheus A., Alisjahbana A., Vranckx R., Sukadi A., Usman A., Ngantung W.et al. Immunogenicity of a recombinant DNA hepatitis B vaccine in neonates. Postgrad Med J. 63(Suppl. 2):1987;139-141.
23. Poovorawan Y., Sanpavat S., Pongpunlert W., Chumdermpadetsuk S., Sentrakul P., Safary A. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA. 261:1989;3278-3281.
24. Poovorawan Y., Sanpavat S., Pongpunlert W., Chumdermpadetsuk S., Sentrakul P., Chitinand S.et al. Comparison of a recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage. Vaccine. 8(Suppl.):1990;S56-S59.
25. Panda S.K., Ramesh R., Rao K.V.S., Gupta A., Zuckerman A.J., Nayak N.C. Comparative evaluation of the immunogenicity of yeast-derived (recombinant) and plasma-derived hepatitis B vaccine in infants. J Med Virol. 35:1991;297-302.
26. Lolekha S., Bowonkiratikachorn P., Chimabutra K. Immunogenicity and reactogenicity of a yeast-derived hepatitis B vaccine in Thai school children. J Med Assoc Thai. 72(Suppl. 1):1989;98-101.
27. Barone P., Mauro L., Leonardi S., Ienna M., Bilancia G.G., Falcidia E.et al. Simultaneous administration of HB recombinant vaccine with diphtheria and tetanus toxoid and oral polio vaccine. A pilot study Acta Paediatr Jpn. 33:1991;455-458.
28. Tsega E., Tafesse B., Horton J., Nordenfelt E., Wolde-Hawariat G., Hansson B.G.et al. Immunogenicity, reactogenicity and comparison of two doses of recombinant DNA yeast-derived hepatitis B vaccine in Ethiopian children. Trop Geogr Med. 43:1991;220-227.
29. Scaravelli C., Bianchi E., Biraghi V., Mariani G., Calligari G.C., Lucchesi P.et al. Efficacy of minimal doses of an American hepatitis B vaccine in neonates. Clin Ther. 7:1985;680-683.
30. Stevens C.E., Taylor P.E., Tong M.J., Toy P.T., Vyas G.N., Nair P.V.et al. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B transmission. JAMA. 257:1987;2612-2616.
31. Greenberg DP, Vadheim CM, Marcy CM, et al. Comparative safety and immunogenicity of two recombinant hepatitis B (HBV) vaccines given to infants at 2, 4, and 6 months of age. Program and abstracts of 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, October 1992: 264.
32. Hwang L.Y., Lee C.Y., Beasley R.P. Five year follow-up of HBV vaccination with plasma-derived vaccine in neonates. Evaluation of immunogenicity and efficacy against perinatal transmission Hollinger F.B., Lemon S.M., Margolis H.S. Viral Hepatitis and Liver Disease. 1991;Williams & Wilkins, Baltimore, MD.
33. Lee G.C.Y., Hwang L.Y., Beasley R.P., Chen S.H., Lee T.Y. Immunogenicity of hepatitis B virus vaccine in healthy Chinese neonates. J Infect Dis. 148:1983;526-529.
34. Greenberg D.P., Vadheim C.M., Wong V.K., Marcy M., Partridge S., Greene T.et al. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age. Pediatr Infect Dis J. 15:1996;590-596.
35. Niu M.T., Davis D.M., Ellenberg S. Recombinant hepatitis B vaccination of infants. Emerging safety data from the Vaccine Adverse Event Reporting System (VAERS) Pediatr Infect Dis J. 15:1996;771-776.
36. Chen R.T., Rastogi S.C., Mullen J.R., Hayes S.W., Cochi S.L., Donlon J.A.et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine. 12:1994;542-550.
37. Chen R.T., Glasser J., Rhodes P., Thompson R.S., Mullooly J.P., Black S.B.et al. The Vaccine Safety Datalink project. A new tool for improving vaccine safety monitoring in the United States Pediatrics. 99:1997;765-773.
38. Roberts J.D., Roos L.L., Poffenroth L.A., Hassard T.H., Bebchuk J.D., Carter A.O.et al. Surveillance of vaccine-related adverse events in the first year of life. A Manitoba cohort study J Clin Epidemiol. 49:1996;51-58.
39. Rosenthal S., Chen R., Hadler S. The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. Arch Pediatr Adolesc Med. 150:1996;457-460.
40. Brown G.W. Nothing to whoop about. Arch Pediatr Adolesc Med. 150:1996;461-463.
41. Chen R., Rosenthal S. An errant critique that misses the mark. Arch Pediatr Adolesc Med. 150:1996;464-465.
42. Braun M.M., Ellenberg S.S. Descriptive epidemiology of adverse events following immunization. Reports to the Vaccine Adverse Event Reporting System (VAERS), 1991-1994 J Pediatr. 131:1997;529-535.
43. Rosenthal S., Chen R. The reporting sensitivities of two passive surveillance systems for Vaccine Adverse Events. Am J Pub Health. 85:1995;1706-1709.
44. Ellenberg S.S., Chen R. The complicated task of monitoring vaccine safety. Pub Health Reports. 112:1997;10-20.
45. Wise R.P., Kiminyo K.P., Salive M.E. Hair loss after routine immunization. JAMA. 278:1997;1176-1178.